A preview of the top trends on the minds of industry and market leaders for the new year.
A Novel Technology Platform for Bone Regeneration and Cancer Treatment
Patients that require reconstruction of large sections of bone and skin currently have limited options. With its 3M3 platform, Novadip Biosciences hopes to change patient lives by offering new regenerative medicine treatment options for patients...
Bench To Boardroom: A Scientist-Turned-CEO’s Journey
Denis Dufrane, M.D., Ph.D. wanted to skip the formal part. An accomplished academic and clinician, he’d spent 15 years at the Université Catholique de Louvain—where he’d earned his M.D. and his Ph.D. in biomedical sciences with a concentration on cell...
Novadip reveals results from severe bone non-union trial
Novadip Biosciences – a company developing regenerative tissue products to accelerate large bone defect healing – announced positive data from its phase 1/2 clinical trial.
Positive Data from Novadip Biosciences Clinical Trial
Novadip Biosciences announced positive data from its Phase I/II clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union (BNU) of the lower limb following trauma.
Novadip bone healing trial yields positive results
Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003.
Résultats encourageants pour le réducteur de fractures de Novadip
Novadip annonce des résultats positifs de l'essai clinique de son traitement expérimental de guérison de fractures osseuses.
Innovation in Tissue Regeneration Improves Spine Fusions and Fracture Repairs
Novadip Biosciences recently received an infusion of €40 million (~USD $40 million) in investments, increasing its total funding to €88 million. The Belgium-based company will use the capital to develop a new class of adipose-derived stem cell (ASC) tissue...
Novadip Biosciences Raises Funds to Support Regenerative Tissue Products
Novadip Biosciences raised an additional €40 million (~USD $40 million) in a Series B equity round and non-dilutive funding. This brings the company’s total funding to €88 million, to date.
Biotech Funding Roundup: HI-Bio’s Haul, Concerto’s Cash, Lusaris’s Launch & More
Tissue regeneration biotech Novadip Biosciences raised €40 million. The cash will go toward two clinical-stage programs: an allogeneic bone union therapeutic called NVD-X3 and NVD-003, an autologous bone engraftment product. The cash breaks down to €24 million in...
Novadip Biosciences raises €40m for orthopaedic products development
Novadip Biosciences, a Belgium-based biopharmaceutical company, has raised an additional €40 million in a Series B equity round and non-dilutive funding.
Novadip Biosciences raises €40M for bone defect treatments
The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment.
Novadip Biosciences Raises Additional $39.1 Million
Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has raised an additional EUR 40 million ($39.1 million) in a Series B...
Novadip raises $22M in series B funding for US trial of bone regeneration therapy
Novadip SA raised €19 million (US$22.1 million) in a first close of a series B round to progress its autologous bone regeneration therapy, NVD-003, on either side of the Atlantic. The company is also working on an allogeneic regenerative approach, which is still...
Restoring the physiology of natural healing
Read this article about Novadip published on the website of biopharmadealmakers.
Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch
Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years.